Osong factory completion in 2013. South Korean PICS/GMP ... · Company History & Overview ......
Transcript of Osong factory completion in 2013. South Korean PICS/GMP ... · Company History & Overview ......
Osong factory completion in 2013.South Korean PICS/GMP Guidelines
©Komipharm International Australia Pty Ltd 1
Company History & Overview
• Yong-Jin Yang – Chairman Komipharm International
• Yong-Jin Yang has over 35 years of experience in the management of pharmaceutical companies.
• In 1981 he established Joong Ang Pharm Co. specialising in the veterinary medicines.
• In 1988 Mr. Yang acquired Komipharm Co. - A veterinary vaccine R&D and manufacturer.
• In early 2001, Komipharm Co. established its human medicine division and begun Research and development of a novel anti-cancer treatment.
• By the end of 2001, Mr. Yang had listed Komipharm International Co. Ltd on the Korean stock exchange (KOSDAQ).
©Komipharm International Australia Pty Ltd 2
• Komipharm International Australia was established in 2015.
• API & Tablet Manufacturing for KOMINOX.
• Komipharm International will have its human drugs for globalmanufacturing, R&D & marketing headquarters in DandenongSouth, Victoria.
• Komipharm currently exports products to 21 countries and hasover 130 distributors worldwide.
©Komipharm International Australia Pty Ltd 3
• Kominox is an arsenic-based new oral drug.
• Compared to arsenic oxides such as As2O3, Kominox showed excellent tolerability.
• Effects of sodium meta-arsenite (NaAsO2) on human cancer cells (MDA-MB-231, MCF-7 and U-87 MG).
• Kominox exerts anticancer activity and cancer pain-relieving efficacy by regulating gene expression and signal pathways in human body.
• Several human clinical trails were held in the USA; Europe; Korea and Asian countries.
• Clinical trials showed that Kominox was effective for Prostate, Breast, Brain, Blood, Lung & Liver.
• The effectiveness is on the Stem Cells and Telomerase.
• In Australia Kominox has a TGA Category B SAS registration.
©Komipharm International Australia Pty Ltd 4
Antitumor effect of Kominox in HuCCT-1 xenograft nude mouse model (After 28 days)A: Control, B: Kominox 3.5mg/kg, C: Kominox 7mg/kg, D: Gemcitabine-HCl 3.5mg/kg
Antitumor effect of Kominox in a xenograft nude mouse model
©Komipharm International Australia Pty Ltd 5
Victorian State Government Partnership
• Appointed a consultant.
• Identified Government Departments.
• Identified Ministers responsible for their constituency,
• Identified Trade ministers team.
• Department heads.
• Grant evaluation which would suite our project.
• Why LIFT?
• Komipharm South Korea vision and partnership.
©Komipharm International Australia Pty Ltd 6
Parliament & Department Networking
• Komipharm made contact on both sides of politics.
• Premier –Hon Daniel Andrews MP
• Small Business, Innovation & Trade – Hon Philip Dalidakis MLC
• Industry & Employment – Hon Wade Noonan MP
• Dandenong MP – Gabrielle Williams
• Shadow Minister for Trade & Employment- Craig Ondarchie MP
• Shadow Minister for Innovation – David Southwick MP
• Department of Eco Development –
Tony Rajic & Team
©Komipharm International Australia Pty Ltd 7
Detailed Overview of the Project
• Key activities reflecting how the project funds will be spent (e.g. purchase of new equipment, etc)
• Expected outcomes (e.g., increased employment, expanded business capability and/or capacity, new product/service, etc)
• What is the demand for your proposed project (product/service) from the target market?
• Implementation Plan and Budget.
• Explain why the project is necessary?
• What will the project bring to gaps identified?
• Outline any identified risks associated with your project
©Komipharm International Australia Pty Ltd 8
Concept Design & Engineering
• Market Research for Engineering company for scope of works.
• Gaps found and merger acquisitions and transition period.
• FEED
• Concept Design
• Automation
• IT Integration
• API
• Equipment
• Laboratory
©Komipharm International Australia Pty Ltd 10
©Komipharm International Australia Pty Ltd 11
Board Of Directors & Management Team
Bong-Kyu SongDirector Osong Factory
Sang-Han KimDirector Osong Factory
Yong-Jin Yang Chairman Komipharm International Co Ltd
Heewon SeoDirector & Secretary Komipharm Int Australia Doug Neumann
Project Engineering Manager
Charles FridlenderExecutive Director Komipharm Int Australia
Shelly Freeman Legal PRO Manager
QA
MM
ADMPM
Front Entrance
Internal 1
Internal 2
Context site representation